encorafenib

1 Drug classified under this active ingredient

Kinase Inhibitor. encorafenib 75 mg.
Hard Caps.180 x 75 mg
BRAF V600E or V600K Mutation-Positive Unresectable or Metast. Melanoma and for BRAF V600E Mutation-Positive Metast. Non-Small Cell Lung Cancer (NSCLC)- recommended dosage is 450 mg (six 75 mg caps.) orally 1 X d in combin. with binimetinib until dis. progress. or unacceptable tox.
BRAF V600E Mutation-Positive Metast. Colorectal Cancer (CRC)- recommended dosage is 300 mg (four 75 mg capsules) orally 1 X d in combin. with cetuximab until dis. progress. or unacceptable tox.
For adults with:
BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma or
BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC)-  as detected by an approved test, after prior ther.
BRAF V600E Mutation-Positive metastatic non-small cell lung cancer (NSCLC)- in combin. with binimetinib, when mutation detected by an approved test.
 C/I:  Hypersens.